Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
Journal
The Lancet Oncology
Journal Volume
13
Journal Issue
5
Pages
539-548
Date Issued
2012
Author(s)
Su W.-C.
Hsia T.-C.
Tsai C.-M.
Ou S.H.I.
Chang G.-C.
Ho C.-L.
Sequist L.V.
Dudek A.Z.
Shahidi M.
Cong X.J.
Lorence R.M.
Miller V.A.
Abstract
Background: Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of afatinib in patients with lung adenocarcinoma and EGFR mutations. Methods: In this phase 2 study, we enrolled patients from 30 centres in Taiwan and the USA with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) with EGFR mutations, who had no more than one previous chemotherapy regimen for advanced disease, an Eastern Cooperative Oncology Group performance status of 0-2, and no previous treatment with EGFR tyrosine-kinase inhibitors. We tested two afatinib starting doses: 50 mg daily and subsequently 40 mg daily, introduced to establish whether tolerability could be improved with retention of anti-tumour activity. The primary endpoint was the proportion of patients with a confirmed objective response (complete response or partial response), on the basis of Response Evaluation Criteria in Solid Tumors 1.0 (independent review). This study is registered with ClinicalTrials.gov, number NCT00525148. Findings: 129 patients were treated with afatinib, 99 with a starting dose of 50 mg and 30 with a starting dose of 40 mg. 79 (61%) of 129 patients had an objective response (two complete responses, 77 partial responses). 70 (66%) of the 106 patients with the two common activating EGFR mutations (deletion 19 or L858R) had an objective response, as did nine (39%) of 23 patients with less common mutations. Similar proportions of patients had an objective response when analysed by starting dose (18 [60%] of 30 patients at 40 mg vs 61 [62%] of 99 patients at 50 mg). Of the two most common adverse events (diarrhoea and rash or acne), grade 3 events were more common in patients receiving a 50 mg starting dose (22 [22%] of 99 patients for diarrhoea and 28 [28%] of 99 patients for rash or acne) than they were in those receiving a 40 mg starting dose (two [7%] of 30 patients for both diarrhoea and rash or acne); possibly treatment-related serious adverse events were also less common in patients receiving a 40 mg starting dose (two of 30 patients vs 14 of 99 patients). We recorded one possibly drug-related death (interstitial lung disease). Interpretation: Afatinib shows activity in the treatment of patients with advanced lung adenocarcinoma with EGFR mutations, especially in patients with deletion 19 or L858R mutations. The efficacy of afatinib 40 mg should be compared with chemotherapy or other EGFR tyrosine-kinase inhibitors in EGFR-mutation-positive NSCLC. Funding: Boehringer Ingelheim Inc. ? 2012 Elsevier Ltd.
SDGs
Other Subjects
afatinib; acne; adult; aged; article; cellulitis; decreased appetite; diarrhea; drug dose comparison; drug dose reduction; drug efficacy; drug response; drug tolerability; drug withdrawal; dry skin; epidermal growth factor receptor gene; epistaxis; eye disease; fatigue; female; gene mutation; heart left ventricle ejection fraction; human; human tissue; interstitial lung disease; kidney failure; lung adenocarcinoma; major clinical study; male; multicenter study; muscle spasm; nail disease; nausea; overall survival; phase 2 clinical trial; pneumothorax; priority journal; progression free survival; proteinuria; pruritus; rash; receptor gene; rhinorrhea; sex difference; side effect; stomatitis; treatment outcome; vomiting; weight reduction; xerosis; Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor, Epidermal Growth Factor
Type
journal article